Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX)
(Delayed Data from NSDQ)
$1.24 USD
+0.11 (9.73%)
Updated May 16, 2024 04:00 PM ET
After-Market: $1.25 +0.01 (0.81%) 5:30 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Biodexa Pharmaceuticals PLC Unsponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 6 | 4 | 14 | 10 | 14 |
Receivables | 1 | 2 | 2 | 2 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 8 | 6 | 16 | 12 | 18 |
Net Property & Equipment | 1 | 1 | 2 | 1 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 3 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 3 | 0 | 0 | 0 | 16 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 11 | 7 | 18 | 13 | 39 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 2 | 2 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 0 | 1 | 2 | 1 |
Total Current Liabilities | 6 | 2 | 3 | 4 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 1 | 1 | 0 | 7 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 3 | 3 | 4 | 14 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 7 | 1 | 2 | 1 | 1 |
Capital Surplus | 94 | 103 | 115 | 95 | 84 |
Retained Earnings | -157 | -167 | -176 | -157 | -127 |
Other Equity | 61 | 66 | 74 | 69 | 67 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 5 | 4 | 14 | 9 | 25 |
Total Liabilities & Shareholder's Equity | 11 | 7 | 18 | 13 | 39 |
Total Common Equity | 5 | 4 | 14 | 9 | 25 |
Shares Outstanding | 1.20 | 0.00 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | 4.22 | 3.91 | 14.37 | 8.63 | 24.97 |
Fiscal Year End for Biodexa Pharmaceuticals PLC Unsponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 6 | -99,999 | -99,992 | -99,999 |
Receivables | NA | 1 | NA | 3 | NA |
Notes Receivable | NA | 0 | NA | NA | NA |
Inventories | NA | 0 | NA | NA | NA |
Other Current Assets | NA | 0 | NA | NA | NA |
Total Current Assets | NA | 8 | NA | 9 | NA |
Net Property & Equipment | NA | 1 | NA | 1 | NA |
Investments & Advances | NA | 0 | NA | NA | NA |
Other Non-Current Assets | NA | 0 | NA | NA | NA |
Deferred Charges | NA | 0 | NA | NA | NA |
Intangibles | NA | 3 | NA | 0 | NA |
Deposits & Other Assets | NA | 0 | NA | NA | NA |
Total Assets | NA | 11 | NA | 10 | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | NA | NA |
Accounts Payable | NA | 1 | NA | 2 | NA |
Current Portion Long-Term Debt | NA | 0 | NA | 0 | NA |
Current Portion Capital Leases | NA | 0 | NA | NA | NA |
Accrued Expenses | NA | 0 | NA | NA | NA |
Income Taxes Payable | NA | 0 | NA | NA | NA |
Other Current Liabilities | NA | 5 | NA | 0 | NA |
Total Current Liabilities | NA | 6 | NA | 3 | NA |
Mortgages | NA | 0 | NA | NA | NA |
Deferred Taxes/Income | NA | 0 | NA | NA | NA |
Convertible Debt | NA | 0 | NA | NA | NA |
Long-Term Debt | NA | 0 | NA | 0 | NA |
Non-Current Capital Leases | NA | 0 | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | NA | NA | |
Minority Interest (Liabilities) | NA | 0 | NA | NA | NA |
Total Liabilities | NA | 6 | NA | 3 | NA |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | NA | NA |
Common Stock (Par) | NA | 7 | NA | 7 | NA |
Capital Surplus | NA | 94 | NA | 106 | NA |
Retained Earnings | NA | -157 | NA | -174 | NA |
Other Equity | NA | 61 | NA | 68 | NA |
Treasury Stock | NA | 0 | NA | NA | NA |
Total Shareholder's Equity | NA | 5 | NA | 7 | NA |
Total Liabilities & Shareholder's Equity | NA | 11 | NA | 10 | NA |
Total Common Equity | 0 | 5 | 0 | 100,006 | 0 |
Shares Outstanding | 1.20 | 1.20 | 1.20 | 1.20 | 0.00 |
Book Value Per Share | 0.00 | 4.22 | 0.00 | 83,338.03 | 0.00 |